Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Liabilities and Shareholders Equity (2016 - 2020)

Monopar Therapeutics (MNPR) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $18.2 million as the latest value for Q3 2020.

  • Quarterly Liabilities and Shareholders Equity rose 255.4% to $18.2 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $43.8 million through Dec 2020, up 44.03% year-over-year, with the annual reading at $13.4 million for FY2019, 82.46% up from the prior year.
  • Liabilities and Shareholders Equity hit $18.2 million in Q3 2020 for Monopar Therapeutics, up from $12.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $18.2 million in Q3 2020 to a low of $2.9 million in Q4 2016.
  • Historically, Liabilities and Shareholders Equity has averaged $9.2 million across 5 years, with a median of $8.4 million in 2018.
  • Biggest five-year swings in Liabilities and Shareholders Equity: crashed 35.23% in 2019 and later soared 255.4% in 2020.
  • Year by year, Liabilities and Shareholders Equity stood at $2.9 million in 2016, then skyrocketed by 242.98% to $9.9 million in 2017, then dropped by 26.31% to $7.3 million in 2018, then skyrocketed by 82.46% to $13.4 million in 2019, then skyrocketed by 35.98% to $18.2 million in 2020.
  • Business Quant data shows Liabilities and Shareholders Equity for MNPR at $18.2 million in Q3 2020, $12.8 million in Q2 2020, and $12.8 million in Q1 2020.